Stanley Erck, Novavax CEO (Andrew Harnik, AP Images)
September 24, 2021 07:39 AM EDTUpdated 10:21 AM
Coronavirus

Covid-19 roundup: SAB's an­ti­body treat­ments move to PhI­II; Af­ter long jour­ney, No­vavax sub­mits vac­cine to WHO for re­view

Josh Sullivan

A day af­ter the com­pa­ny lands an­oth­er $60.5 mil­lion to help ad­vance an an­ti­body Covid-19 treat­ment, SAB Bio­ther­a­peu­tics has an­nounced a pos­i­tive re­view from the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

WuXi AppTec will sell cell and gene ther­a­py busi­ness to pri­vate eq­ui­ty firm

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

Three drug­mak­ers sue US over 340B dis­counts to STD clin­ics they al­lege don’t qual­i­fy

A service from the Financial Times